Elevated prothrombin time/international normalized ratio associated with concurrent administration of regorafenib and warfarin in a patient with advanced colorectal cancer

BACKGROUND: Regorafenib and its metabolites may inhibit the activities of several CYP or UDP-glucuronosyltransferase isoforms, including that of CYP2C9. Therefore, pharmacological agents that are CYP2C9 substrates may show elevated circulating levels and enhanced drug efficacy when concurrently used...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pharm Health Care Sci
Main Authors: Kitade, Hironori, Hiromasa-Yamasaki, Azusa, Hokkoku, Kengo, Mori, Mitsue, Watanabe, Michio, Nakai, Masuo, Yano, Seiji
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2016
Assuntos:
Case Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4937497/
https://ncbi.nlm.nih.gov/pubmed/27398225
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40780-016-0050-y
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados